Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017

September 2017 | 39 pages | ID: H073234141DEN
Global Markets Direct

Abstracts

Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017, provides an overview of the Hepatic - Colorectal Metastasis (Oncology) pipeline landscape.

Patients who present with hepatic colorectal metastases are usually asymptomatic. Symptoms such as abdominal pain and weight loss are associated with advanced (high-volume) metastases and a poor prognosis. Although liver resection is not the primary treatment for most patients with hepatic colorectal metastases, appropriate liver resection is the standard of care for treatment of patients with isolated hepatic colorectal metastases.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatic - Colorectal Metastasis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hepatic - Colorectal Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatic - Colorectal Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatic - Colorectal Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II and Phase I stages are 2 and 4 respectively.

Hepatic - Colorectal Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatic - Colorectal Metastasis (Oncology).
• The pipeline guide reviews pipeline therapeutics for Hepatic - Colorectal Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hepatic - Colorectal Metastasis (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hepatic - Colorectal Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hepatic - Colorectal Metastasis (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hepatic - Colorectal Metastasis (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hepatic - Colorectal Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Hepatic - Colorectal Metastasis - Overview
Hepatic - Colorectal Metastasis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hepatic - Colorectal Metastasis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatic - Colorectal Metastasis - Companies Involved in Therapeutics Development
Alfact Innovation
Cellular Biomedicine Group Inc
Delcath Systems Inc
Gradalis Inc
Hepatic - Colorectal Metastasis - Drug Profiles
ALF-5755 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBM-EGFR.1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
contusugene ladenovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gemogenovatucel-T - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSVRbp-450 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melphalan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatic - Colorectal Metastasis - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hepatic - Colorectal Metastasis, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Hepatic - Colorectal Metastasis - Pipeline by Alfact Innovation, H2 2017
Hepatic - Colorectal Metastasis - Pipeline by Cellular Biomedicine Group Inc, H2 2017
Hepatic - Colorectal Metastasis - Pipeline by Delcath Systems Inc, H2 2017
Hepatic - Colorectal Metastasis - Pipeline by Gradalis Inc, H2 2017
Hepatic - Colorectal Metastasis - Dormant Projects, H2 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hepatic - Colorectal Metastasis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Alfact Innovation
Cellular Biomedicine Group Inc
Delcath Systems Inc
Gradalis Inc